Literature DB >> 8008003

Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy.

C E Jackson1, R J Barohn, L J Ptacek.   

Abstract

The diagnosis of paramyotonia congenita (PC) can be aided by demonstrating a decrease in compound motor action potential amplitude after exercise and a decrement on repetitive stimulation, following cold exposure. We report a patient with PC who presented with complaints of cold-induced hand and jaw stiffening, in the absence of any episodes of weakness. Treatment with mexiletine led to resolution of the abnormalities exhibited during a short exercise test and repetitive stimulation following ice bath immersion. Molecular genetic analysis revealed a missense mutation (cytosine to thymidine) on chromosome 17 in the alpha-subunit of the skeletal muscle sodium channel gene that results in the replacement of threonine with methionine. This case demonstrates that, despite the absence of weakness, the short exercise test following cold exposure can be used to confirm the diagnosis of PC in patients without episodic weakness. Furthermore, improvement of the electrophysiologic abnormalities with mexiletine was documented, corresponding with clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008003     DOI: 10.1002/mus.880170710

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

Review 1.  Inherited disorders of voltage-gated sodium channels.

Authors:  Alfred L George
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

3.  Phenotypic variation of a Thr704Met mutation in skeletal sodium channel gene in a family with paralysis periodica paramyotonica.

Authors:  J Kim; Y Hahn; E H Sohn; Y J Lee; J H Yun; J M Kim; J H Chung
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

4.  Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel.

Authors:  M P Takahashi; S C Cannon
Journal:  J Physiol       Date:  2001-12-15       Impact factor: 5.182

5.  Characterization of a new sodium channel mutation at arginine 1448 associated with moderate Paramyotonia congenita in humans.

Authors:  S Bendahhou; T R Cummins; H Kwiecinski; S G Waxman; L J Ptácek
Journal:  J Physiol       Date:  1999-07-15       Impact factor: 5.182

6.  A practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Viatcheslav Stepanenko; Melvin De Jesús; Wildeliz Correa
Journal:  J Org Chem       Date:  2008-08-09       Impact factor: 4.354

7.  Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.

Authors:  Ging Kuo Wang; Corinna Russell; Sho-Ya Wang
Journal:  J Physiol       Date:  2003-11-07       Impact factor: 5.182

Review 8.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

9.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

10.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.